JP Morgan Chase’s AbCellera Biologics ABCL Stock Holding History
Bought
Maintained
Sold
Other funds holding ABCL
BBA
JP Morgan Chase's ABCL Position: Q3 2026 in Review
JP Morgan Chase increased its AbCellera Biologics (ABCL) stake by 31% in Q3 2026, buying an estimated $65.2K and bringing the position to 28,725 shares worth $426K. The position accounts for ﹤0.01% of the portfolio, ranked #5325.
JP Morgan Chase first reported a position in ABCL in Q4 2021 and has held it in 20 quarters since. The position peaked at $6.01M in Q4 2022. 164 funds tracked by Wall St. Rank hold ABCL as of Q3 2026.
- JP Morgan Chase held 28,725 shares of AbCellera Biologics worth $426K as of Q3 2026.
- JP Morgan Chase bought 6,874 AbCellera Biologics shares in Q3 2026, an estimated $65.2K.
- AbCellera Biologics made up ﹤0.01% of JP Morgan Chase's portfolio in Q3 2026, its #5325 holding.
- JP Morgan Chase first reported a position in AbCellera Biologics in Q4 2021 and has held it in 20 quarters since.
- JP Morgan Chase's AbCellera Biologics position peaked at $6.01M in Q4 2022.
- 164 funds tracked by Wall St. Rank held AbCellera Biologics as of Q3 2026.
Based on JP Morgan Chase's 13F filing for Q3 2026, filed 12 Nov 2026.